Mosaic ImmunoEngineering Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPMV research report →
Price Chart
About the company
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health.
- CEO
- Steven W. King
- IPO
- 2013
- Employees
- 7
- HQ
- Huntington Beach, CA, US
Get TickerSpark's AI analysis on CPMV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $441.77K
- P/E
- -0.67
- PEG
- 0.02
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -3.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 9.08%
- ROIC
- 9.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-616,119
- Net Income
- $-687,846+25.4%
- EPS
- $-0.10+26.9%
- OCF Growth
- +53.8%
- FCF Growth
- +53.8%
- 52W High
- $1.05
- 52W Low
- $0.05
- 50D MA
- $0.53
- 200D MA
- $0.58
- Beta
- -0.81
- RSI (14)
- 31
- Avg Volume
- 480
No earnings-call transcripts are available for CPMV yet.
- Free Float
- 11.3%
- Shares Outstanding
- 7.24M
- Float Shares
- 819.85K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 22 | KING STEVEN W | other | 0 |
| Feb 18, 22 | FELCYN GLORIA | other | 0 |
| Feb 18, 22 | GARNICK ROBERT L | other | 0 |
| Feb 18, 22 | BAFFI ROBERT | other | 0 |
| Feb 18, 22 | Steinmetz Nicole Franziska | other | 0 |
| Jul 15, 22 | BAFFI ROBERT | other | 51,497 |
| Jul 15, 21 | BAFFI ROBERT | other | 0 |
| May 7, 21 | GARNICK ROBERT L | other | 0 |
| May 7, 21 | FELCYN GLORIA | other | 0 |
| Apr 29, 21 | Steinmetz Nicole Franziska | other | 5,357 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CPMV coverage
Recent articles, reports, and earnings notes.
No research on CPMV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CPMV report →Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update
defenseworld.net · Apr 16
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
accesswire.com · Apr 29
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
accesswire.com · Oct 6
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
accesswire.com · Oct 1
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
accesswire.com · Sep 27
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
accesswire.com · Sep 23
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
accesswire.com · Sep 21
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
accesswire.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.